Marija Vrljic
Vice President, Antibody Technologies ALX Oncology
Dr. Vrljic has served as VP of Antibody Technologies at ALX Oncology since 2021. She was a co-founder of ScalmiBio, an early-stage start-up, acquired by ALX Oncology in 2021. Dr. Vrljic holds Ph.D. in Biophysics and postdoctoral research training from Stanford University. Her work has been focused on interdisciplinary problems that require novel technological solutions and lie at the interface of protein chemistry and biology.
Seminars
Wednesday 25th February 2026
Blending Chemistry & Biology ADC Design: Exploring Rationale- Driven Development of ALX2004 to Maximise Opportunity for Clinical Differentiation
12:00 pm
- Highlighting design and selection of novel Topo1 payload, highlighting rationale for pairing with anti-EFGR antibody
- Presenting preclinical performance of ALX2004 including activity with improved bystander activity and stability versus deruxtecan ADCs
- Sharing rationale and design to maximise therapeutic window and overcome toxicity challenges of the class
